# A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

> **NCT06040372** · PHASE1 · COMPLETED · sponsor: **LG Chem** · enrollment: 112 (actual)

## Conditions studied

- Obese
- Overweight
- Healthy

## Interventions

- **DRUG:** LB64640
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06040372
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-16
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-07-30
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06040372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06040372, "A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06040372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*